Navigation Links
PARI Respiratory's LC PLUS & PRONEB Ultra Deliver Dey, L.P.'s New COPD Therapy; Perforomist Launched Yesterday
Date:10/9/2007

MIDLOTHIAN, Va., Oct. 9 /PRNewswire/ -- PARI Respiratory Equipment's breath-enhanced nebulizer, the PARI LC PLUS, and PRONEB Ultra compressor deliver Dey, L.P.'s new COPD medication, Perforomist Inhalation Solution, that launched nationwide yesterday. Dey, L.P. is a subsidiary of Mylan Inc. (NYSE: MYL).

Perforomist (formoterol fumarate) Inhalation Solution is indicated for long-term, twice-daily maintenance treatment of bronchoconstriction for emphysema and chronic bronchitis, also known as Chronic Obstructive Pulmonary Disease (COPD). Perforomist Inhalation Solution will be available through retail pharmacies, hospitals, long-term care facilities, and home healthcare companies.

"We are extremely pleased that our PARI LC PLUS nebulizer and PRONEB Ultra compressor were chosen exclusively for the clinical trials for Perforomist Inhalation Solution and are on the package insert. PARI's nebulizers and compressors are the top performers in the industry, which makes them a perfect fit for many of DEY's products -- including DuoNeb, AccuNEB, and now Perforomist," said Geoff A. Hunziker, President of PARI in the United States.

Formoterol fumarate is a rapid, long-acting beta(2)-agonist (LABA) that has been previously available in the U.S. as a dry powder formulation and has twenty years of worldwide use.

The safety and efficacy of Perforomist Inhalation Solution have been established in clinical trials when administered using the PARI LC PLUS nebulizer (with a facemask or mouthpiece) and the PARI PRONEB Ultra compressor. The safety and efficacy of Perforomist Inhalation Solution delivered from other compressor-based nebulizer combinations and non-compressor based nebulizer systems have not been established.

The PARI LC PLUS and the PRONEB Ultra are the most frequently used compressor-based nebulizer system for new nebulized medications in clinical development.

About Perforomist Inhalation Solution Indication

Perforomist Inhalation Solution is indicated for the long-term, twice-daily (morning and evening) administration in the maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD) including chronic bronchitis and emphysema.

Important Safety Information

Perforomist Inhalation Solution belongs to a class of medications known as long-acting beta2-adrenergic agonists (LABAs). LABAs may increase the risk of asthma-related death. Data from a large placebo-controlled US study comparing the safety of another LABA (salmeterol) or placebo added to usual asthma therapy showed an increase in asthma-related deaths in patients receiving salmeterol. This finding with salmeterol may apply to formoterol (a LABA), the active ingredient in Perforomist Inhalation Solution.

Perforomist Inhalation Solution should not be used in patients with acutely deteriorating COPD or to treat acute symptoms. Acute symptoms should be treated with fast-acting rescue inhalers. Perforomist Inhalation Solution should not be used with other medications containing LABAs. Do not use more than one nebule twice daily. Perforomist Inhalation Solution should be used with caution in patients with cardiovascular disorders. Perforomist Inhalation Solution is not a substitute for inhaled or oral corticosteroids. The safety and efficacy of Perforomist Inhalation Solution in asthma has not been established.

In COPD clinical trials, the most common adverse events reported with Perforomist Inhalation Solution were diarrhea, nausea, nasopharyngitis, dry mouth, vomiting, dizziness, and insomnia. Please see full Prescribing Information, including Boxed Warning, at http://www.perforomist.com

About COPD

COPD refers to a number of chronic lung disorders in which the airways to the lungs become narrowed and breathing becomes progressively difficult. The most common forms of COPD are chronic bronchitis and emphysema, and many patients suffer from a combination of the two diseases.

COPD is the fourth leading cause of death in America, behind heart disease, cancer, and stroke. Twelve million Americans have been diagnosed with COPD and at least another 12 million have symptoms but are undiagnosed.

Advancements Offered by Nebulization

Perforomist Inhalation Solution is a long-acting bronchodilator that is taken by nebulizer. Of the three types of devices used to deliver bronchodilators -- nebulizers, metered-dose inhalers, and dry powder inhalers -- nebulizers require no special technique or coordination, as the liquid medication is converted into a fine mist that patients inhale through a mouthpiece or face-mask while breathing naturally. Since nebulization is an easy, effective, and thorough method of delivering medication directly into the lungs, many COPD patients ask for it, particularly as their symptoms worsen.

About Dey

Dey, L.P. is a specialty pharmaceutical company focused on the development, manufacturing and marketing of prescription drug products for the treatment of respiratory diseases, respiratory-related allergies, and emergency care medicine. Dey, L.P. is a subsidiary of Mylan Inc. (NYSE: MYL).

About PARI Respiratory Equipment, Inc.

PARI is a leading worldwide developer and manufacturer of fast and efficient aerosol delivery systems for patients with asthma, chronic lung disease, and cystic fibrosis. PARI's worldwide vision is to improve the lives of those affected by respiratory diseases and those who care for them. Maker of the world's leading breath-enhanced reusable nebulizer, the PARI LC PLUS, and the new PARI LC Sprint nebulizer line, PARI also manufactures the award-winning PARI TREK S compact compressor, the innovative aerosol mask Bubbles the Fish II, and powerful PARI PRONEB Ultra II. PARI's North American headquarters is in Midlothian, VA with worldwide headquarters in Starnberg, Germany. Online at http://www.Pari.com

Additional information is available by contacting Ayars & Associates at 805-566-2986 or Ashley Weigand at 804-253-7274 x711.


'/>"/>
SOURCE PARI Respiratory Equipment, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. High-Throughput System Generates Ultra-Pure PCR Products Suitable for All Applications
2. Efficient Recovery of Ultrapure Plasmid DNA
3. Ultra-Fast Purification of Small Nucleic Acids
4. Inactivation of Contaminating Templates in PCR Using High Intensity Ultraviolet Light
5. Analysis of urine and seawater samples by ultrasonic nebulization with a high resolution ICP spectrometer
6. REPLI-g UltraFast Mini Kit
7. GE Healthcare leads compact ultrasound market
8. GE introduces compact ultrasound system for women
9. pFB-ERV: Retroviral Delivery of the Ecdysone Receptor Proteins
10. High-Titer Retroviral Vectors for Gene Delivery
11. Unique Enhanced DNA Polymerase Delivers High Fidelity and Great PCR Performance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , Dec. 8, 2016 Soligenix, Inc. (OTCQB: ... focused on developing and commercializing products to treat rare ... today that it will be hosting an Investor Webcast ... on the origins of innate defense regulators (IDRs) as ... of oral mucositis and the recently announced and published ...
(Date:12/8/2016)... Dec. 8, 2016 Eutilex Co. Ltd. today ... (US $18.9M) Series A financing. This financing round included ... Venture and SNU Bio Angel. This new funding brings ... KRW (US $27.7M) since its founding in 2015. ... the development and commercialization of its immuno-oncology programs, expand ...
(Date:12/7/2016)... , ... December 07, 2016 , ... ... its phase I/II dose escalation and expansion clinical trial for its lead drug ... Austria. The purpose of the trial was to determine the safety, antitumor activity, ...
(Date:12/7/2016)... 2016 Neogen Corporation (NASDAQ: NEOG ... Kephart as its chief science officer — a ... responsibilities at Neogen effective Jan. 1. Kephart ... agribusiness unit of Thermo Fisher Scientific, as well as ... His extensive industry experience also includes the management of ...
Breaking Biology Technology:
(Date:12/6/2016)... , Dec. 6, 2016  Zimmer Biomet Holdings, Inc. ... has priced an offering of €500.0 million principal amount of ... principal amount of its 2.425% senior unsecured notes due 2026. ... to occur on December 13, 2016, subject to the satisfaction of ... annual basis. The Company intends ...
(Date:12/6/2016)... DALLAS , Dec. 6, 2016 ... criminal justice technology solutions for public safety, investigation, ... (PEP) jointly announced today a five (5) year ... exclusive agreement to expand the rehabilitation and reentry ... PEP History Established in 2004, the Prison ...
(Date:12/2/2016)... , December 1, 2016 ... (Fingerprint, Voice), Future Technology (Iris Recognition System), Vehicle ... - Global Forecast to 2021", published by MarketsandMarkets, ... Million in 2016, and is projected to grow ... CAGR of 14.06%.      (Logo: http://photos.prnewswire.com/prnh/20160303/792302) ...
Breaking Biology News(10 mins):